سعر انسومان بيزال 100 وحدة دولية / مل 5*3 مل اقلام 2022

Insuman Basal: intermediate-acting isophane (NPH) human insulin suspension, 100 IU/ml, pack of 5 cartridges of 3 ml for reusable pens (Sanofi; listed in Egypt as Sanofi > Franco).

• Diabetes mellitus where treatment with insulin is required.Population: Adults and children (EU SmPC does not restrict the population)European Medicines Agency (EMA) - EPAR product information

• Hypoglycaemia is the most frequent adverse reaction. Common: oedema and injection-site reactions; uncommon: shock, injection-site urticaria; also reported: immediate-type allergic reactions, anti-insulin antibodies, sodium retention, transient visual impairment and temporary worsening of diabetic retinopathy, lipodystrophy and cutaneous amyloidosis.International label, same product · European Medicines Agency (EMA) - EPAR product information

• Hypersensitivity to insulin human or to any of the excipients.International label, same product · European Medicines Agency (EMA) - EPAR product information
• Contraindicated during episodes of hypoglycaemia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Transfer to another type or brand of insulin must be done under strict medical supervision; changes in strength, brand, type, origin or manufacturing method may require a dose change, immediately or over several weeks.International label, same product · European Medicines Agency (EMA) - EPAR product information
• Hypoglycaemia may occur if the dose is too high; warning symptoms may be reduced in long-standing diabetes, autonomic neuropathy, the elderly, psychiatric illness or with certain medicines. Exercise, missed meals, alcohol, intercurrent illness and some endocrine disorders increase the risk. Medication errors between insulins have occurred; check the label before each injection.International label, same product · European Medicines Agency (EMA) - EPAR product information
• Cases of cardiac failure have been reported when pioglitazone was combined with insulin, especially in patients with risk factors; observe for heart failure, weight gain and oedema.International label, same product · European Medicines Agency (EMA) - EPAR product information

• Oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, propoxyphene, salicylates, sulphonamide antibioticsMay enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia.European Medicines Agency (EMA) - EPAR product information
• Corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens/progestogens, phenothiazines, somatropin, sympathomimetics, thyroid hormones, protease inhibitors, atypical antipsychotics (e.g. olanzapine, clozapine)May reduce the blood-glucose-lowering effect of insulin.European Medicines Agency (EMA) - EPAR product information
• Beta-blockers, clonidine, lithium salts, alcohol, pentamidine, guanethidine, reserpineMay potentiate or weaken the glucose-lowering effect; pentamidine may cause hypoglycaemia followed by hyperglycaemia; sympatholytics may mask adrenergic warning signs of hypoglycaemia.European Medicines Agency (EMA) - EPAR product information

• No clinical data on exposed pregnancies are available for insulin human; insulin does not cross the placenta. Use with caution; good metabolic control throughout pregnancy is essential in pre-existing or gestational diabetes.International label, same product · European Medicines Agency (EMA) - EPAR product information
• No effects on the breastfed child are anticipated; can be used during breastfeeding, but insulin dose and diet may need adjustment.International label, same product · European Medicines Agency (EMA) - EPAR product information

• Insulin isophane human (NPH): Lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production; as an isophane suspension it has a gradual onset and long duration of action compared with soluble insulin.